Dublin, Ireland, January 31, 2020 –
Inflection Biosciences Ltd, a company developing innovative therapeutics for the treatment of cancer, today announced that the company has been selected to present at the BIO CEO & Investor Conference 2020, which is being held in New York on February 10 – 11. Now in its 22nd year, the BIO CEO & Investor Conference is one of the largest independent investor conferences focused on established and emerging publicly traded and select private biotech companies.
Inflection Biosciences’ presentation will be given by Darren Cunningham, Chief Executive Officer, on Tuesday, February 11, at 9.30 a.m. ET in the Brecht Room at the Marriott Marquis, New York.
About Inflection Biosciences
Inflection Biosciences Ltd, based in Dublin, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments was licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises the first-in-class AUM300 series (PIM/PI3K/mTOR inhibitors) partnered with AUM Biosciences, internal programs IBL-202 (PIM/PI3K inhibitor) and the IBL-100 series (selective pan-PIM kinase inhibitors), currently in pre-clinical stages of development. Data generated to date suggests potential application in a range of treatment resistant solid tumours and haematological malignancies. Inflection Biosciences was named ‘Start-up Company of the Year’ at the 2014 Irish Pharma Awards. For more information please visit www.inflectionbio.com